Structure-based discovery of A2A adenosine receptor ligands

Area of Science:

• Medicinal Chemistry
• Structural Biology
• Pharmacology

Background:

• G protein-coupled receptors (GPCRs) are crucial drug targets, with recent X-ray structures enabling structure-based ligand discovery.
• The A(2A) adenosine receptor is implicated in CNS and peripheral signaling, with therapeutic potential for neurodegenerative diseases and inflammation.

Purpose of the Study:

• To discover novel chemotypes for the A(2A) adenosine receptor using structure-based ligand design.
• To identify potent and selective small molecules for modulating A(2A) adenosine receptor activity.

Main Methods:

• Utilized molecular docking to screen a large compound database against the A(2A) adenosine receptor X-ray structure.
• Experimentally tested 20 high-ranking, novel compounds for biological activity and receptor subtype selectivity.

Main Results:

• 35% of tested compounds exhibited significant activity, with affinities ranging from 200 nM to 9 microM.
• The most potent inhibitors demonstrated over 50-fold specificity for A(2A) over A(1) and A(3) adenosine receptor subtypes.
• Identified novel ligands dissimilar from known compounds, suggesting new avenues for drug development.

Conclusions:

• Structure-based screening is effective for discovering novel chemotypes targeting GPCRs like the A(2A) adenosine receptor.
• The identified compounds represent promising lead structures for developing therapeutics for conditions involving A(2A) receptor modulation.
• Commercial library bias towards GPCR-like structures was observed, yet novel and potent inhibitors were still discovered.